Viridian Therapeutics
VRDN
26 hedge funds and large institutions have $8.36M invested in Viridian Therapeutics in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 9 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.09% less ownership
Funds ownership: 1.35% → 1.27% (-0.09%)
7% less funds holding
Funds holding: 28 → 26 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
30% less capital invested
Capital invested by funds: $11.9M → $8.36M (-$3.59M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$305K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$149K |
| 3 |
VF
Virtu Financial
New York
|
+$111K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$86.5K |
| 5 |
BCV
Banque Cantonale Vaudoise
Lausanne,
Switzerland
|
+$49.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$477K |
| 2 |
Squarepoint
New York
|
-$132K |
| 3 |
GPFA
Game Plan Financial Advisors
Westlake,
Ohio
|
-$77K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$71K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$18K |
VRDN Hedge Fund Activity: Q3 2020 in Review
26 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2020, worth a combined $8.36M — down 30% from $11.9M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of VRDN and 7 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was Qube Research & Technologies (QRT), adding an estimated $305K. The largest seller was Renaissance Technologies, cutting an estimated $477K.
- 26 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2020, down from 28 in Q2 2020.
- Funds reported $8.36M of Viridian Therapeutics stock for Q3 2020, down 30% quarter-over-quarter.
- 7 funds opened new Viridian Therapeutics positions in Q3 2020 and 9 closed out, a net change of -2 holders.
- The largest Viridian Therapeutics buyer in Q3 2020 was Qube Research & Technologies (QRT), an estimated $305K added.
- The largest Viridian Therapeutics seller in Q3 2020 was Renaissance Technologies, an estimated $477K sold.
Based on aggregated 13F filings for Q3 2020.